End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
29 THB | +0.87% | +0.87% | +4.50% |
Summary
- The company has strong fundamentals. More than 70% of companies have a lower mix of growth, profitability, debt and visibility.
- The company presents an interesting fundamental situation from a short-term investment perspective.
Strengths
- The company's EBITDA/Sales ratio is relatively high and results in high margins before depreciation, amortization and taxes.
- The company returns high margins, thereby supporting business profitability.
- The company is in a robust financial situation considering its net cash and margin position.
- Over the past year, analysts have regularly revised upwards their sales forecast for the company.
- Over the last 4 months, analysts have significantly revised upwards the company's estimated sales.
- For the last twelve months, analysts have been gradually revising upwards their EPS forecast for the upcoming fiscal year.
- For the last few months, EPS revisions have remained quite promising. Analysts now anticipate higher profitability levels than before.
- Analysts have a positive opinion on this stock. Average consensus recommends overweighting or purchasing the stock.
- The average target price set by analysts covering the stock is above current prices and offers a tremendous appreciation potential.
- Over the past twelve months, analysts' opinions have been strongly revised upwards.
- Considering the small differences between the analysts' various estimates, the group's business visibility is good.
- Analysts' price targets are all relatively close, reflecting good visibility on the company's valuation.
- Historically, the company has been releasing figures that are above expectations.
Weaknesses
- With an expected P/E ratio at 29.35 and 26.9 respectively for both the current and next fiscal years, the company operates with high earnings multiples.
- With an enterprise value anticipated at 4.21 times the sales for the current fiscal year, the company turns out to be overvalued.
- The company appears highly valued given the size of its balance sheet.
- The valuation of the company is particularly high given the cash flows generated by its activity.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Healthcare Facilities & Services
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
+4.50% | 12.38B | B | ||
-18.46% | 16.57B | B+ | ||
+4.31% | 11.73B | B+ | ||
+24.94% | 8.4B | B | ||
-2.64% | 7.63B | A- | ||
+20.04% | 7.16B | D | ||
+3.96% | 6.63B | B- | ||
+46.90% | 4.58B | - | ||
-5.70% | 4.22B | - | ||
-4.82% | 4.18B | - |
Financials
Valuation
Momentum
Consensus
Business Predictability
Environment
Governance
Controversy
- Stock Market
- Equities
- BDMS Stock
- Ratings Bangkok Dusit Medical Services